Completed PHASE2 INTERVENTIONAL 1-arm NCT00758225

Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

A Phase II Open-label Extension Study to Obtain Long-term Safety, Tolerability and Efficacy Data of Idebenone in the Treatment of Duchenne Muscular Dystrophy - Extension to Study SNT-II-001

Sponsor: Santhera Pharmaceuticals

Conditions Duchenne Muscular Dystrophy

Interventions Idebenone

Updated 5 times since 2017 Last updated: May 30, 2011 Started: Sep 30, 2008 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00758225, this PHASE2 trial focuses on Duchenne Muscular Dystrophy and remains completed. Sponsored by Santhera Pharmaceuticals, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Santhera Pharmaceuticals

Data source: Santhera Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium